MedTrace Logo

The Effects of Wheat Sprouts Supplements on the Key Health Indicators of the Patients With Breast Cancer After Chemotherapy

NCT04998994 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-08-10

No results posted yet for this study

Summary

To explore the effects of wheat sprouts supplements on the key health indicators of the patients with breast cancer after chemotherapy, Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy and nutritional status, immune function, quality of life were measured and evaluated. Through data analysis, we found that Maiji tablets may improve the symptoms of appetite loss, nausea and vomiting, and fatigue in patients with breast cancer during chemotherapy. Meanwhile it may help patients maintain weight, keep appetite and improve the food intake.

Conditions

  • Nutritional Status, Immune Function, Quality of Life Uring the Progress of Chemotherapy

Interventions

DIETARY_SUPPLEMENT

wheat sprouts supplement

Maiji tablets, a wheat sprouts supplement, were used to treat 26 patients during the progress of chemotherapy

Sponsors & Collaborators

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Quzhou Kecheng People's Hospital

    collaborator UNKNOWN

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Jinhua Municipal Central Hospital

    collaborator OTHER

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2020-08-22
Completion
2020-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04998994 on ClinicalTrials.gov